நீண்டது கால நீட்டிப்பு சோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நீண்டது கால நீட்டிப்பு சோதனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நீண்டது கால நீட்டிப்பு சோதனை Today - Breaking & Trending Today

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

LEO Pharma
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
Monday, April 26, 2021 1:00PM IST (7:30AM GMT)

Ballerup, Denmark & Madison, N.J., United States:

Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients
1
Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two years
1
1

LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021. ....

United States , Linda Mayer , Andrew Blauvelt , Oregon Medical Research Center , Global Research , European Medicines Agency On , American Academy Of Dermatology Virtual Meeting Experience , National Library Of Medicine , Committee For Medicinal Products Human Use , Global Product Communications , American Academy , Dermatology Virtual Meeting Experience , Investigator Global Assessment , Eczema Area , Severity Index , Executive Vice President , Medicinal Products , Human Use , European Medicines Agency , Term Extension , Improvements Observed , Tralokinumab Treatment , Moderate To Severe Atopic Dermatitis , Interim Readout , Long Term Extension , Long Term Extension Trial ,

Redirecting to LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

2.0 (2.4)
Participants included 1,174 patients from ECZTEND at data cut-off.1 Observed outcomes for all patients enrolled 60 weeks prior to data cut-off (n=513) were analyzed at Week 56.1 At parent-trial baseline, ECZTEND baseline, and Week 56, median EASI score was 26.6, 4.7, and 1.8, respectively.1 At Week 56, IGA and EASI response rates were 49.7% (IGA 0/1), 95.1% (EASI-50), 82.8% (EASI-75), 61.0% (EASI-90), and 79.7% (EASI ≤7). An EASI score of ≤7 corresponds to mild atopic dermatitis.1
At the same 56-week data cut-off, measurements of itch and sleep disruptions due to itch were also reported.1 At Week 56, the mean worst weekly pruritus (i.e. itch) numeric rating scale (NRS) score was 3.3 (parent-trial baseline was 7.7) while the mean eczema-related weekly sleep NRS score was 2.0 (parent-trial baseline was 6.9).1 ....

United States , Andrew Blauvelt , Oregon Medical Research Center , American Academy Of Dermatology Virtual Meeting Experience , Global Research , National Library Of Medicine , European Medicines Agency On , Committee For Medicinal Products Human Use , American Academy , Dermatology Virtual Meeting Experience , Investigator Global Assessment , Eczema Area , Severity Index , Executive Vice President , Medicinal Products , Human Use , European Medicines Agency , Term Extension , Improvements Observed , Tralokinumab Treatment , Moderate To Severe Atopic Dermatitis , Interim Readout , Long Term Extension , Long Term Extension Trial , Subjects With Atopic Dermatitis Who Participated , Previous Tralokinumab Trials ,

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavant s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.
The following poster will be viewable on the conference platform for the entirety of the conference:
Title:
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent ....

United States , Bruce Strober , April Armstrong , Laurence Watts , Annam Tallman , Robert Bissonnette , Mark Lebwohl , Angela Salerno Robin , Philipm Brown , Kostenloser Wertpapierhandel , Kara Stancell , Andrew Blauvelt , Roivant Sciences , Program For Tapinarof , Dermavant Sciences , Linkedin Dermavant Sciences , Investor Relations Corporate Communications , Dermatology Virtual Spring Conference , Tapinarof Cream , Once Daily , Plaque Psoriasis , Interim Analysis , Long Term Extension Trial , Linda Stein Gold , Leon Kircik , North America ,